

Electronic Acknowledgement Receipt

EFS ID:	3076101
Application Number:	10571405
International Application Number:	
Confirmation Number:	7796
Title of Invention:	Quinoline compounds and pharmaceutical compositions containing them
First Named Inventor/Applicant Name:	Christopher Norbert Johnson
Customer Number:	20462
Filer:	Kathryn Lutomski Sieburth/Arlene Cannon
Filer Authorized By:	Kathryn Lutomski Sieburth
Attorney Docket Number:	PB60501
Receipt Date:	31-MAR-2008
Filing Date:	10-MAR-2006
Time Stamp:	11:48:09
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$300
RAM confirmation Number	7307
Deposit Account	192570
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1		PB60501Response.pdf	682832	yes	14
			7e50bc6f1d386c4de4ff203310966a5f0a3c3d3		
Multipart Description/PDF files in .zip description					
Document Description		Start	End		
Amendment - After Non-Final Rejection		1	1		
Specification		2	7		
Claims		8	10		
Applicant Arguments/Remarks Made in an Amendment		11	13		
Abstract		14	14		
Warnings:					
Information:					
2		PB60501IDS.pdf	131323	yes	3
			b5a344777e730611d7ba31a3c7c6a8ba3dc745ea		
Multipart Description/PDF files in .zip description					
Document Description		Start	End		
Information Disclosure Statement Letter		1	2		
Information Disclosure Statement (IDS) Filed		3	3		
Warnings:					
Information:					
3	Foreign Reference	1WO2002100822A1.pdf	4488350	no	131
			b766aedd1782096320f8b1f85d51042e408b2cf7		
Warnings:					
Information:					

4	Foreign Reference	2WO200063203A1.pdf	3039977 1924810c416c8ba05649178a15c9977a3 c170b0	no	76
Warnings:					
Information:					
5	Foreign Reference	3WO2003042208A1.pdf	1927681 da6d1aadae980c203b11c955ed4ee85c da95c339	no	61
Warnings:					
Information:					
6	Foreign Reference	4WO2003037872A1.pdf	5742465 76c78b47a49ab5039557307c44111a15 234eb03c	no	160
Warnings:					
Information:					
7	Foreign Reference	5WO2003037871A1.pdf	5743031 0990b736c4589621a4fb2733c0c897810 bc39ade	no	137
Warnings:					
Information:					
8	Foreign Reference	6WO200042026A1.pdf	6120477 5ea78eb114e8c38798a0b674e0c05936 0130a2d4	no	194
Warnings:					
Information:					
9	Foreign Reference	7WO2003080580A2.pdf	2275381 7f9548b611211b3ab37a25ca8b17ed8955 8413a224	no	48
Warnings:					
Information:					
10	Foreign Reference	8WO2003035061A1.pdf	947044 545c3e6a7496b0b44675ab3c0db678c5 01nb322	no	32
Warnings:					
Information:					
11	NPL Documents	9Woolley_Neuropharm_2001.pdf	258731 a3da2748b2002a18b876vda016a275a 97c678a1	no	10
Warnings:					
Information:					
12	NPL Documents	10Mitchell_Pharmacol_Ther_2005.pdf	2006749 be1175a9dda3c6322980207e48a3a8 70E0711	no	14
Warnings:					
Information:					

13	NPL Documents	11Chuang_Alz_Dementia.pdf	594503 46cd44201560511da3cd71e8e70e3032b650b6	no	5
Warnings:					
Information:					
14	NPL Documents	12London_SE_Announcemnt_2007.pdf	329366 de9448c4359285ab030c3c5229789d7882463339	no	4
Warnings:					
Information:					
15	NPL Documents	13Dose_Ranging_Study_SB742457_2007.pdf	131689 d9c3123045a930de103d1bc97503a4dc2c5690	no	4
Warnings:					
Information:					
16	NPL Documents	14SB742457_Donepezil_AD_2006.pdf	130389 25a59c7b5676917a28e-ec1602cd32b78475cd21b4	no	4
Warnings:					
Information:					
17	NPL Documents	15Garcia_Alloza_Neuropsychopharm_2004.pdf	1039342 e085789a820f5d4513dd8a4764f76c4f7438c0f	no	7
Warnings:					
Information:					
18	Fee Worksheet (PTO-06)	fee-info.pdf	8370 0aa0fc51a3b6a2632ade6d6b351829a150cae0	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			35597700		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.